Showing results (101-110 of 128) with videos related to
Sort By:
Pageof 13
American Journal of Hematology|August 16, 2023
The CAR-HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCLKai Rejeski, Yucai Wang, Omar Albanyan, et al.Journal of the National Comprehensive Cancer Network : JNCCN|September 6, 2018
Chimeric Antigen Receptor T-Cell TherapyNdiya Ogba, Nicole M Arwood, Nancy L Bartlett, et al.Journal of Oncology Practice|January 1, 2015
If you did not document it, it did not happen: rates of documentation of discussion of infertility risk in adolescent and young adult oncology patients' medical recordsGwendolyn P Quinn, Rebecca G Block, Marla L Clayman, et al.Blood Advances|February 24, 2026
MRD-driven initial therapy of acalabrutinib and lenalidomide plus rituximab or obinutuzumab for mantle cell lymphomaJia Ruan, David A Bond, Bijal Shah, et al.Blood|July 25, 2022
The role of allogeneic transplant for adult Ph+ ALL in CR1 with complete molecular remission: a retrospective analysisArmin Ghobadi, Michael Slade, Hagop Kantarjian, et al.Cardio-Oncology (London, England)|April 3, 2023
Cardiac and inflammatory biomarker differences in adverse cardiac events after chimeric antigen receptor T-Cell therapy: an exploratory studyDae Hyun Lee, Sanjay Chandrasekhar, Michael D Jain, et al.Blood|January 29, 2021
Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphomaMichael D Jain, Hua Zhao, Xuefeng Wang, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 17, 2020
Tumor Microenvironment Composition and Severe Cytokine Release Syndrome (CRS) Influence Toxicity in Patients with Large B-Cell Lymphoma Treated with Axicabtagene CiloleucelRawan Faramand, Michael Jain, Verena Staedtke, et al.Transplantation and Cellular Therapy|September 29, 2022
Outcomes of CD19-Targeted Chimeric Antigen Receptor T Cell Therapy for Patients with Reduced Renal Function Including DialysisAnthony C Wood, Ariel Perez Perez, Brian Arciola, et al.Nature Communications|April 19, 2017
Unification of de novo and acquired ibrutinib resistance in mantle cell lymphomaXiaohong Zhao, Tint Lwin, Ariosto Silva, et al.Pageof 13